PAV-trial: Plerixafor and Chemotherapy With Vinorelbine for Stem Cell Mobilization in Patients With Myeloma

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patientpatients mustcellstagechemotherapy
  Phrases that lowered it: accordinglineapplicationhematologicalcontaining
• Sponsor's past termination rate: 3.4% (lowers risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Responsible party: not given (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Maximum age: 70 (lowers risk) · Who can join
• Minimum age: 18 (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 24.6% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 96.7% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Number of arms: 1 (raises risk) · Design
• Disease area, dermatology: No (lowers risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 238 (raises risk) · Drug's FDA history
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Allocation: not applicable (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Plerixafor in Treating Patients With Multiple Myeloma Previously Treated With Lenalidomide and Planning to Undergo Autologous Stem Cell Transplant NCT00998049 · started 2009 · scored riskier than 83% of active trials completed
• A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma). NCT00838357 · started 2008 · scored riskier than 41% of active trials completed
• Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma NCT02220608 · started 2015 · scored riskier than 94% of active trials completed
• Plerixafor Plus Granulocyte Colony-stimulating Factor (G-CSF) For Mobilization And Collection Of Peripheral Hematopoietic Stem Cells In Japanese Participants With Multiple Myeloma NCT02221479 · started 2014 · scored riskier than 67% of active trials completed
• Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma NCT01919086 · started 2013 · scored riskier than 28% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.